Insys stock: buy or sell?
June 28th, 2019
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States.
Should I buy Insys stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to define your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Insys stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Insys stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 2 ratings published for INSY stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-3-8||Royal Bank of Canada||Outperform||Outperform|
Insys stock analysis
After sliding for 4 sessions, June Insys boosted a super good 25,307,307,592.31%, closing at $65,799,000.00.
After sliding for 4 days, June Insys boosted a super good 25,307,307,592.31%, closing at $65,799,000.00. Since last June when SMA100d and SMA200d crossed up, INSY price gained $65,798,999.74 per share (25,307,307,592.31%). INSY broke out again over $0.74 after a 72.97% correction started on June.
Insys shares broke up the SMA line of 200d, closing at $65,799,000.00. By mid June INSY plunged a bloodcurdling -30.77% in just one week.
Since late June when SMA20w and SMA40w crossed up, INSY price gained $65,798,999.74 per share (25,307,307,592.31%).
Insys stock price history
Insys stock went public on November 2nd, 2017 with a price of $4.791. Since then, INSY stock surged a 1,373,674,221.50%, with a yearly average of 1,373,674,221.50%. If you had invested $1,000 in Insys stock in 2017, it would worth $13,736,742,215.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Insys stock historical price chart
INSY stock reached 52-week highs at $11.65, and all-time highs 2018-01-03 with a price of 14.
Insys stock price target is $7.00How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we only found 1 price target for Insys Therapeutics stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-3-8||Royal Bank of Canada||Lowers Target||$9.00||$7.00||-22.2%|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Insys reported its latest financial data, posting a phenomenal gain for the Earnings per Share (EPS) ratio. Analyst were expecting $-0.33 per share, but Insys Therapeutics posted $-0.39.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw a spooky loss of -41.66% to $82.08 M dollars. When comparing 2018 vs 2017, improving that, profit margin (that is, the net income divided by revenues) rose a 9.54% to -151.69%.
|2013||$99 M||-||$40 M40.7%||-|
|2014||$222 M||123.71%||$38 M17.1%||-5.95%|
|2015||$331 M||48.92%||$58 M17.7%||53.98%|
|2016||$242 M||-26.76%||$7.59 M3.1%||-87.02%|
|2017||$141 M||-41.93%||$-226.84 M-161.2%||-3,088.60%|
|2018||$82 M||-41.66%||$-124.51 M-151.7%||-45.11%|
Quarterly financial resultsInsys reported $16.36 million in sales for 2018-Q4, a -10.84% less compared to previous quarter. Reported quarter income marked $-46.29 million with a profit margin of -283.02%. Profit margin plummed a -116.80% compared to previous quarter when profit margin was -166.22%. When comparing sales to same quarter last year, Insys Therapeutics sales marked a frightening drop down and collapsed a -48.05%. Looking back to recent quarterly results, Insys posted 4 positive quarters in a row.
|2017-Q1||$36 M||-||$-6.52 M-18.1%||-|
|2017-Q2||$43 M||18.41%||$-8.18 M-19.2%||25.46%|
|2017-Q3||$31 M||-27.97%||$-166.32 M-542.3%||1,933.25%|
|2017-Q4||$31 M||2.66%||$-47.11 M-149.6%||-71.68%|
|2018-Q1||$24 M||-24.06%||$-20.37 M-85.2%||-56.76%|
|2018-Q2||$23 M||-1.86%||$-27.35 M-116.6%||34.27%|
|2018-Q3||$18 M||-21.82%||$-30.49 M-166.2%||11.50%|
|2018-Q4||$16 M||-10.84%||$-46.29 M-283.0%||51.81%|
Insys ownershipWhen you are planning to buy shares of a stock, it's worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Insys, of all outstanding shares are owned by its staff.
The following table compares ownership indicators for other stocks related to Insys Therapeutics:
|Market cap||$0.0 M|
|Total shares||0.0 M|
|Float shares||0.0 M|
|- Institutional holdings (%)||0.0%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Friday, June 28th, 2019|
|Day range||$0.25 - $0.38|
|Average true range||$0.31|
|50d mov avg||$1,315,980.00|
|100d mov avg||$657,994.00|
|200d mov avg||$329,000.00|
Insys performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We picked as the bechmarking frame for Insys Therapeutics stock.